Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial) Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial)

Putting the "Bio" Back Into Biomarkers: Orienting Proteomic Discovery Toward Biology and Away from the Measurement Platform (Editorial‪)‬

Clinical Chemistry, 2008, Jan, 54, 1

    • 2,99 €
    • 2,99 €

Beschreibung des Verlags

The discipline of mass spectrometry (MS)-based serum biomarker profiling is a relatively young field that was launched in a flourish of scientific hope and the clinical promise of a better cancer test (1-5). Nevertheless, the field has already undergone a rollercoaster cycle of optimism and disappointment and renewed enthusiasm during its brief 7-year history (1-8). Before 1999 very little effort was made to directly use MS (MALDI-TOF or ES) as a means to discover new blood biomarkers. Many scientists thought that serum was too complex for MS analysis, and dominated by contaminants, rendering these samples unacceptable for direct introduction into expensive and sophisticated MS research instruments. All of these arguments seemed to be overturned in 1998 when a new class of MALDI-TOF, surface-enhanced laser desorption and ionization (SELDI) was commercialized. Scientists with no formal training in MS saw SELDI as an opportunity to explore the application of MALDI MS to biomarker discovery. Although this method had relatively low resolution, it appeared to provide a fresh, one-step approach to the search for ion signatures of hundreds of candidate biomarkers. Importantly, SELDI-TOF offered a means to support a critical new hypothesis that was emerging in the protein biomarker field. This hypothesis abandoned the assumption that a single specific tumor cell-derived cancer biomarker existed. Instead, cascades of biomarkers were generated from the tumor tissue microenvironment through interactions between the tumor cells and the host cells (e.g., endothelial cells, stroma cells, and immune cells) (1, 5). The tissue-microenvironment hypothesis predicted that a panel of biomarkers could achieve a sensitivity and specificity superior to previous failed cancer biomarker searches (1, 5-8). In 2002 SELDI provided a means for discovering the ion signatures of these putative biomarkers, although their identity was unknown (1, 2).

GENRE
Wissenschaft und Natur
ERSCHIENEN
2008
1. Januar
SPRACHE
EN
Englisch
UMFANG
8
Seiten
VERLAG
American Association for Clinical Chemistry, Inc.
ANBIETERINFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
GRÖSSE
188,6
 kB
Biomarker Discovery and Validation (Editorials) Biomarker Discovery and Validation (Editorials)
2006
SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer (Proteomics and Protein Markers) (Clinical Report) SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer (Proteomics and Protein Markers) (Clinical Report)
2008
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
Bioinformatics and Biomarker Discovery Bioinformatics and Biomarker Discovery
2011
The Role of the Study Director in Nonclinical Studies The Role of the Study Director in Nonclinical Studies
2014
Advancing Disease Modeling in Animal-Based Research in Support of Precision Medicine Advancing Disease Modeling in Animal-Based Research in Support of Precision Medicine
2018
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report) Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report)
2002
Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs) Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs)
2004
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
A Conversation with Elizabeth Blackburn (Interview) A Conversation with Elizabeth Blackburn (Interview)
2009
The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective) The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective)
1998